Substance / Medication

Cholestyramine

Overview

Active Ingredient
cholestyramine resin
RxNorm CUI
2447

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

20 trials linked to this intervention

20
Total Trials
0
Recruiting
10
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The cholestyramine-induced decrease of PYY postprandial response is negatively correlated with fat mass in obese women.
Rigamonti A E, Resnik M, Compri E et al. · Horm Metab Res · 2011
PMID: 21769759RCT
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
Krasuski Richard A, Devendra Ganesh P, Cater George et al. · Am J Med Sci · 2011
PMID: 21358314RCT
Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin.
Mibielli Marco Antonio, Nunes Carlos Pereira, Cohen José Carlos et al. · Proc West Pharmacol Soc · 2010
PMID: 22128442RCT
Cholestyramine--a useful adjunct for the treatment of patients with fecal incontinence.
Remes-Troche Jose M, Ozturk Ramazan, Philips Carrie et al. · Int J Colorectal Dis · 2008
PMID: 17938939RCT
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial.
Calabrese Carlo, Fabbri Anna, Areni Alessandra et al. · J Gastroenterol Hepatol · 2007
PMID: 17565633RCT
Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated.
Sjöberg Beatrice G, Straniero Sara, Angelin Bo et al. · Am J Physiol Endocrinol Metab · 2017
PMID: 28487440Trial
Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine.
Singhal Rohit, Harrill Alison H, Menguy-Vacheron Francoise et al. · BMC Pharmacol Toxicol · 2014
PMID: 25086653TrialFull text (PMC)
Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression.
Nilsson L-M, Abrahamsson A, Sahlin S et al. · Biochem Biophys Res Commun · 2007
PMID: 17448444Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Colestyramine (substance)
SNOMED CT
387408001
UMLS CUI
C0008402
RxNorm CUI
2447

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
20
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.